erlotinib hydrochloride has been researched along with daunorubicin in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (daunorubicin) | Trials (daunorubicin) | Recent Studies (post-2010) (daunorubicin) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 8,239 | 886 | 1,310 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | daunorubicin (IC50) |
---|---|---|---|
72 kDa type IV collagenase | Homo sapiens (human) | 1.9 | |
Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.047 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.22 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.02 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chalfant, CE; Goehe, RW; Hawkins, AJ; Massiello, A; Mayton, EK; Mukerjee, P; Murudkar, CS; Park, MA; Pinkerman, RL; Shultz, JC; Wijesinghe, DS | 1 |
1 other study(ies) available for erlotinib hydrochloride and daunorubicin
Article | Year |
---|---|
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Topics: Alternative Splicing; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Erlotinib Hydrochloride; HeLa Cells; Humans; Introns; Lung Diseases; Nuclear Proteins; Paclitaxel; Quinazolines; RNA Precursors; RNA Splice Sites; RNA-Binding Proteins; RNA, Antisense; RNA, Small Interfering; Serine-Arginine Splicing Factors | 2011 |